Study of CP-675,206 in Refractory Melanoma
Basic Trial Information
|Phase II||Treatment||Completed||18 and over||Pharmaceutical / Industry||A3671008|
CP-675,206 is a fully human monoclonal antibody (mAb). It binds to the CTLA4 molecule, which is expressed on the surface of activated T lymphocytes. CP-675,206 is thought to stimulate patients' immune systems to attack their tumors. CP-675,206 is not expected to have a direct effect on tumor cells. CP-675,206 been shown to induce durable tumor responses in patients with metastatic melanoma in Phase 1 and Phase 2 clinical studies.
- Surgically incurable Stage III or IV melanoma
- One prior systemic treatment for metastatic melanoma
- Measurable disease
- Eastern Cooperative Oncology Group (ECOG) PS = 0 or 1
- Melanoma of ocular origin
- Received prior vaccine
- Received prior CTLA4-inhibiting agent
- History of, or significant risk for, chronic inflammatory or autoimmune disease
- Potential requirement for systemic corticosteroids
Trial Contact Information
Trial Lead Organizations/Sponsors
AstraZeneca Pharmaceuticals LP
Link to the current ClinicalTrials.gov record.
NLM Identifier NCT00254579
ClinicalTrials.gov processed this data on May 20, 2015
Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.